Rheumatic Heart Disease Management Market
Number of pages: 100 | Report Format: PDF | Published date: March 17, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 1.10 billion |
|
Revenue Forecast in 2031 |
US$ 1.66 billion |
|
CAGR |
4.7% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global rheumatic heart disease management market was valued at US$ 1.10 billion in 2022 and is expected to register a revenue CAGR of 4.7% to reach US$ 1.66 billion by 2031.
Rheumatic Heart Disease Management Market Fundamentals
The most significant consequence of rheumatic fever is rheumatic heart disease (RHD). The cause of acute rheumatic fever and RHD is assumed to be an immunological reaction, although the knowledge of specific pathophysiology is lacking. RHD is caused by irreversible heart valve damage due to acute rheumatic fever and rheumatic carditis, including pericarditis, myocarditis, or valvulitis. Mitral valve stenosis with different degrees of regurgitation, atrial dilatation, arrhythmias, and ventricular dysfunction are all symptoms of chronic RHD.
The common symptoms of RHD are shortness of breath, chest discomfort, and exhaustion. However, the patient may not exhibit symptoms in some cases until the disease has advanced to a severe stage. This medical condition can result in substantial morbidity and death, particularly if untreated. It can also cause heart failure, stroke, and other consequences, thus, negatively influencing the quality of the patient’s life. Depending on the severity of the condition, RHD therapy also includes pharmacological and surgical therapies. The major objective of RHD treatment is to avoid or control the disease’s consequences. Antibiotics are the primary line of defense against recurrent group A streptococcal infections, which can aggravate RHD. Anti-coagulants are also employed to prevent blood clots from developing in the heart. Surgical procedures are also commonly used to treat RHD. Valve repair or replacement surgery may be required to remedy RHD-caused valve damage.
Percutaneous balloon mitral valvuloplasty is a minimally invasive technique in which a balloon is inflated in the constricted valve to expand it and enhance blood flow. This treatment is frequently used to address mitral stenosis, a typical RHD consequence. Prevention is an essential component of RHD management.
[56756]
Rheumatic Heart Disease Management Market Dynamics
The global rheumatic heart disease management market is primarily driven by several factors, including the increasing prevalence of RHD, growing awareness about the disease, and advances in medical technology. A key driver of the rheumatic heart disease management market is the rising prevalence of the disease. According to a recent study by the World Heart Federation, RHD affects 40 million people worldwide. It claims that more than 300,000 lives each year, accounting for nearly 2% of all deaths from cardiovascular disease, the number one cause of death globally. The high burden of the disease has led to an increased demand for RHD management products and services, driving market revenue growth. The development of new medical technologies, such as minimally invasive surgical procedures, has made RHD management more effective and less invasive, leading to improved patient outcomes. Growing awareness about RHD is also contributing to the revenue growth of the market.
Governments in several countries are actively promoting RHD prevention and management through initiatives, such as screening programs, public education campaigns, and funding for RHD research. Furthermore, the availability of government initiatives and funding for RHD management is expected to drive market revenue growth.
Limited management procedures with poor diagnostics techniques, stringent regulatory policies, and lack of awareness among the people can complicate the market situation, hampering the overall revenue growth of the global market.
Rheumatic Heart Disease Management Market Ecosystem
The global rheumatic heart disease management market has been analyzed from three perspectives: drug class, end user, and region.
Rheumatic Heart Disease Management Market by Drug Class
[54644]
Based on the drug class, the global rheumatic heart disease management market can be further segmented into anti-inflammatory, anti-coagulant, antibiotics, and others.
The antibiotics segment registered for the largest share in terms of sales in the global rheumatic heart disease management market in 2022 and is expected to retain its dominance during the forecast period, as antibiotics are an essential part of the management and prevention of RHD. Rheumatic fever, the primary cause of RHD, is caused by a bacterial infection, usually group A streptococcus. Antibiotics are used to treat the infection and prevent the development of RHD. Antibiotics are also used to manage RHD to prevent the recurrence of rheumatic fever, which can cause further damage to the heart valves. Patients with RHD are often prescribed prophylactic antibiotics to prevent the recurrence of rheumatic fever and reduce the risk of valve damage. In addition, antibiotic therapy is used to manage infective endocarditis, a serious complication of RHD. Infective endocarditis is an infection of the heart valves or inner lining of the heart, which can cause damage to the valves and lead to heart failure. Antibiotics are used to treat the infection and prevent further valve damage. In addition, the use of antibiotics in RHD management has been supported by various international organizations, including the American Heart Association. These organizations have recommended using antibiotics to prevent and manage RHD, driving the demand for antibiotics in the market.
The anti-inflammatory drugs segment is estimated to depict steady revenue growth during the forecast period, as inflammation plays a significant role in the development and progression of RHD. Anti-inflammatory medications, such as nonsteroidal anti-inflammatory drugs and corticosteroids, can help reduce inflammation and prevent further damage to the heart valves. They are commonly used to manage the symptoms of RHD, such as joint pain and swelling, and to prevent disease progression. Other medications may also be used to manage RHD, such as antibiotics to treat the underlying streptococcal infection and medications to manage heart failure or other complications that may arise.
Rheumatic Heart Disease Management Market by End User
Based on the end user, the global rheumatic heart disease management market can be further segmented into hospitals, ambulatory surgical centers, and others.
The hospitals segment accounts for the largest revenue share in the global market. Hospitals typically have specialized departments, such as cardiology, and are highly equipped with the necessary expertise and facilities to effectively diagnose and manage RHD. These departments are staffed with trained physicians and healthcare professionals with experience managing the disease. Hospitals typically also have access to advanced technology and equipment, such as echocardiography machines, which are necessary for accurate diagnosis and monitoring of RHD. This type of medical setting also offers comprehensive care for RHD patients, including medical management, surgical interventions, and rehabilitation services. This type of care is necessary to effectively manage RHD, which can be a complex and chronic disease. Hospitals are often easily accessible for patients, especially in urban areas with multiple hospitals. This accessibility can be important for patients who require urgent medical attention for RHD-related complications.
Rheumatic Heart Disease Management Market by Region
Based on the region, the global rheumatic heart disease management market can be further segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America leads the rheumatic heart disease management market in terms of revenue, and this trend is likely to continue during the forecast period. The growing urbanization in this region is a primary driver of the market. Constant development in this region leads to an unhealthy lifestyle, which causes obesity and, therefore, an increase in the incidence of heart ailments, expecting market development.
Europe accounts for the second-highest revenue share of the market. Increased acceptance and implementation of sophisticated technology and improved healthcare infrastructure are all contributing to the revenue growth of the rheumatic heart disease management market in this region.
The market in Asia Pacific is expected to grow significantly throughout the forecast period. Some key drivers of the market in Asia Pacific include the growing older population, the fast-increasing prevalence of cardiovascular diseases, the rise in the acceptability and knowledge of ablation cardiovascular disease therapy, and the growth in the number of ablation product manufacturers. Developing markets, such as China, India, Brazil, and Mexico, have also gained traction among firms involved in cardiac ablation device research, production, and marketing.
Rheumatic Heart Disease Management Market Competitive Landscape
Key healthcare companies undertake the development, manufacture, and marketing of pharmaceuticals, vaccines, and consumer health-related products. Expansion initiatives, promising pipeline products, and product approvals could provide revenue growth opportunities for the companies.
The prominent players operating in the global rheumatic heart disease management market are:
The antibiotics segment dominates the global rheumatic heart disease management market with the largest revenue share.
The global rheumatic heart disease management market is expected to register a revenue CAGR of 4.7% during the projected period.
Asia Pacific is projected to be the fastest-growing region in the global rheumatic heart disease management market.
Pfizer Inc, Novartis AG, and Abbott Laboratories Inc. are some of the prominent market players.
The rheumatic heart disease management market is projected to reach US$ 1.66 billion by 2031.
*Insights on financial performance are subject to the availability of information in the public domain